XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Segment Information
 3 Months Ended
Jun. 30, 2021
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information

 

As of June 30, 2021, we had four reportable segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Instruments, and Continuous Monitoring. 

 

 

  

Three Months Ended June 30,

 
  

2021

  

2020

 

Total revenues (a)

        

Sterilization and Disinfection Control

 $15,150  $13,067 

Biopharmaceutical Development

  8,877   5,949 

Instruments

  7,562   7,680 

Continuous Monitoring

  3,331   3,245 

Total revenues (a)

 $34,920  $29,941 
         

Gross profit (loss)

        

Sterilization and Disinfection Control

 $11,428  $10,021 

Biopharmaceutical Development

  4,692   4,466 

Instruments

  4,660   4,688 

Continuous Monitoring

  1,452   1,185 

Reportable segment gross profit

  22,232   20,360 

Corporate and Other (b)

  (21)  (20)

Gross profit

 $22,211  $20,340 

Reconciling Items:

        

Operating expenses

  19,088   16,770 

Operating income

  3,123   3,570 

Nonoperating expense, net

  1,705   2,816 

Earnings before income taxes

 $1,418  $754 

 

 

(a)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

 

(b)

Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other. 

 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information. 

 

  

June 30,

  

March 31,

 
  

2021

  

2021

 

Sterilization and Disinfection Control

 $2,254  $2,333 

Biopharmaceutical Development

  4,907   4,162 

Instruments

  3,304   3,253 

Continuous Monitoring

  1,657   1,430 

Total inventories

 $12,122  $11,178